Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sempra (SREA) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Sempra (SREA) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Sempra's Cost of Revenue rose 173.45% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year increase of 46.55%. This contributed to the annual value of $5.3 billion for FY2024, which is 223.53% down from last year.
  • Latest data reveals that Sempra reported Cost of Revenue of $1.3 billion as of Q3 2025, which was up 173.45% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Sempra's Cost of Revenue registered a high of $1.5 billion during Q4 2023, and its lowest value of $1.0 billion during Q1 2021.
  • Over the past 5 years, Sempra's median Cost of Revenue value was $1.2 billion (recorded in 2021), while the average stood at $1.3 billion.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 1762.63% in 2021, then crashed by 705.18% in 2025.
  • Over the past 5 years, Sempra's Cost of Revenue (Quarter) stood at $1.2 billion in 2021, then grew by 3.94% to $1.3 billion in 2022, then increased by 16.1% to $1.5 billion in 2023, then decreased by 2.33% to $1.5 billion in 2024, then decreased by 7.92% to $1.3 billion in 2025.
  • Its Cost of Revenue stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.